Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases

Dallas N, Samuel S, Xia L, Fan F, Gray M, Lim S, Ellis L (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14:1931–1937

McAllister K, Grogg K, Johnson D, Gallione C, Baldwin M, Jackson C, Helmbold E, Markel D, McKinnon W, Murrell J, McCormick M, Pericak-Vance M, Heutink P, Oostra B, Haitjema T, Westerman C, Porteous M, Guttmacher A, Letarte M, Marchuk D (1994) Endoglin, a TGF-bold beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345–351

Berg J, Porteous M, Reinhardt D, Gallione C, Holloway S, Umasunthar T, Lux A, McKinnon W, Marchuk D, Guttmacher A (2003) Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK 1 mutations. J Med Genet 40:585–590

Govani F, Shovlin C (2009) Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 17:860–871

Piao M, Tokunaga O (2006) Significant expression of endoglin (CD105), TGFβ-1 and TGFβ R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb 13:82–89

Moses J, Leon M, Popma J, Fitzgerald P, Holmes D, O’Shaughnessy C, Caputo R, Kereiakes D, Williams D, Teirstein P, Jaeger J, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323

Holmes DR Jr, Leon M, Moses J, Popma J, Cutlip D, Fitzgerald P, Brown C, Fischell T, Wong S, Midei M, Snead D, Kuntz R (2004) Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109:634–640

Weisz G, Leon M, Holmes DR Jr, Kereiakes D, Clark M, Cohen B, Ellis S, Coleman P, Hill C, Shi C, Cutlip D, Kuntz R, Moses J (2006) Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 47:1350–1355

Weisz G, Leon M, Holmes DR Jr, Kereiakes D, Popma J, Teirstein P, Cohen S, Wang H, Cutlip D, Moses J (2009) Five-year follow-up after sirolimus-eluting stent implantation: results of the SIRIUS (Sirolimus-Eluting Stent in de-novo Native Coronary Lesions) trial. J Am Coll Cardiol 53:1488–1497

Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbæk H, Menichelli M, Sabaté M, Suttorp M, Baumgart D, Seyfarth M, Pfisterer M, Schömig A (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030–1039

Ninomiya J, L’Italien G, Criqui M, Whyte J, Gamst A, Chen R (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109:42–46

Ledue T, Weiner D, Sipe J, Poulin S, Collins M, Rifai N (1998) Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35:745–753

Folland E, Parisi A, Moynihan P, Jones D, Feldman C, Tow D (1979) Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques. Circulation 60:760–766

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated gfr from serum creatinine in Japan. Am J Kidney Dis 53:982–992

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y, Bdolah Y, Lim K, Yuan H, Libermann T, Stillman I, Roberts D, D’Amore P, Epstein F, Sellke F, Romero R, Sukhatme V, Letarte M, Karumanchi S (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642–649

Richard J, Levine R, Lam C, Qian C, Yu K, Maynard S, Sachs B, Sibai B, Epstein F, Romero R, Thadhani R, Karumanchi S (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992–1005

Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M (2003) Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 3:427–432

Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A, Boileau C, Allanore Y (2008) Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology 47:972–975

Conley B, Smith J, Guerrero-Esteo M, Bernabeu C, Vary C (2000) Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153:323–335

Torsney E, Charlton R, Parums D, Collis M, Arthur H (2002) Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 51:464–470

Ma X, Labinaz M, Goldstein J, Miller H, Keon W, Letarte M, O’Brien E (2000) Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 20:2546–2552

Lebrin F, Goumans M, Jonker L, Carvalho R, Valdimarsdottir G, Thorikay M, Mummery C, Arthur H, ten Dijke P (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23:4018–4028

Li C, Bethell H, Wilson P, Bhatnagar D, Walker M, Kumar S (2000) The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis 152:249–256

Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri M, Coli L, De Pasclis A, Lannelli S (2002) Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 61:324–335

Foidart J, Schaaps J, Chantraine F, Munaut C, Lorquet S (2009) Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J Reprod Immuno 82:106–111

Blanco F, Grande M, Langa C, Oujo B, Velasco S, Rodriguez-Barbero A, Perez-Gomez E, Quintanilla M, López-Novoa J, Bernabeu C (2008) S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res 103:1383–1392

Paquet M, Pece-Barbara N, Vera S, Cymerman U, Karabegovic A, Shovlin C, Letarte M (2001) Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum Mol Genet 15:1347–1357

Kimura H, Hiramitsu S, Miyagishima K, Mori K, Yoda R, Kato S, Kato Y, Morimoto S, Hishida H, Ozaki Y (2010) Cardio-renal interaction: impact of renal function and anemia on the outcome of chronic heart failure. Heart Vessels 25:306–312

Coral-Alvarado P, Garces M, Caminos J, Iglesias-Gamarra A, Restrepo J, Quintana G (2010) Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol (Epub 2010 Aug 24)